Stock listing
BME:LAB Labiana Health SA Acciones
Home listing (Madrid) of Labiana Health SA
Follow Labiana Health SA into a list and get an email when it puts out news.
Share price · BME:LAB
€4.76 EUR 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- €4.76 – €4.76 EURNov 20, 2026
- Volume
- 2,575 sharesNov 20, 2026
- Market cap
- €40.41M EURAt the close on Nov 20, 2026 · price × 8.49M shares outstanding
- 52-week range
- €4.24 – €8.20 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €23,140 EURMedian day 2,293 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:LAB · Home | €4.76 EUR | 0.00 (0.0%) | 2,575 | €4.76 | €4.76 | €4.76 | €4.76 | Close on Nov 20, 2026 |
| Frankfurt:8RK | €4.60 EUR | 0.00 (0.0%) | — | €4.64 | €4.64 | €4.60 | €4.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · BME:LAB · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €4.76 | 0.00 | 0.0% | €4.76 | €4.76 | €4.76 | 2,575 | |
| €4.76 | -0.06 | -1.2% | €4.80 | €4.80 | €4.76 | 1,245 | |
| €4.82 | 0.00 | 0.0% | €4.84 | €4.90 | €4.80 | 1,515 | |
| €4.82 | +0.02 | +0.4% | €4.88 | €4.88 | €4.70 | 2,258 | |
| €4.80 | -0.04 | -0.8% | €4.84 | €4.88 | €4.70 | 6,266 | |
| €4.84 | -0.06 | -1.2% | €5.00 | €5.00 | €4.84 | 1,354 | |
| €4.90 | -0.04 | -0.8% | €5.00 | €5.00 | €4.90 | 4,965 | |
| €4.94 | -0.06 | -1.2% | €4.94 | €5.00 | €4.94 | 19,443 | |
| €5.00 | -0.05 | -1.0% | €5.00 | €5.00 | €4.94 | 2,865 | |
| €5.05 | 0.00 | 0.0% | €5.25 | €5.25 | €5.00 | 1,298 | |
| €5.05 | -0.05 | -1.0% | €5.25 | €5.25 | €5.00 | 1,298 | |
| €5.10 | 0.00 | 0.0% | €5.10 | €5.10 | €5.10 | 63 | |
| €5.10 | 0.00 | 0.0% | €5.10 | €5.25 | €5.10 | 752 | |
| €5.10 | -0.10 | -1.9% | €5.15 | €5.15 | €5.05 | 924 | |
| €5.20 | -0.20 | -3.7% | €5.55 | €5.55 | €5.15 | 2,472 | |
| €5.40 | +0.10 | +1.9% | €5.30 | €5.55 | €5.25 | 3,222 | |
| €5.30 | 0.00 | 0.0% | €5.30 | €5.30 | €5.15 | 5,332 | |
| €5.30 | -0.20 | -3.6% | €5.45 | €5.45 | €5.20 | 1,066 | |
| €5.50 | +0.45 | +8.9% | €5.10 | €5.50 | €5.10 | 5,497 | |
| €5.05 | +0.05 | +1.0% | €5.00 | €5.10 | €4.92 | 4,300 | |
| €5.00 | +0.20 | +4.2% | €4.90 | €5.00 | €4.88 | 9,804 | |
| €4.80 | -0.06 | -1.2% | €4.88 | €4.88 | €4.80 | 26,968 | |
| €4.86 | -0.08 | -1.6% | €4.98 | €4.98 | €4.86 | 2,556 | |
| €4.94 | +0.04 | +0.8% | €4.96 | €4.96 | €4.92 | 658 | |
| €4.90 | -0.20 | -3.9% | €5.05 | €5.10 | €4.88 | 9,383 | |
| €5.10 | -0.05 | -1.0% | €5.20 | €5.20 | €4.96 | 4,750 | |
| €5.15 | +0.10 | +2.0% | €5.05 | €5.20 | €5.00 | 2,875 | |
| €5.05 | -0.20 | -3.8% | €5.15 | €5.20 | €5.05 | 3,720 | |
| €5.25 | -0.10 | -1.9% | €5.30 | €5.30 | €5.20 | 13,646 | |
| €5.35 | 0.00 | 0.0% | €5.30 | €5.45 | €4.84 | 52,768 | |
| €5.35 | -0.25 | -4.5% | €5.55 | €5.55 | €5.35 | 10,589 | |
| €5.60 | -0.10 | -1.8% | €5.60 | €5.60 | €5.60 | 1,770 | |
| €5.70 | -0.05 | -0.9% | €5.80 | €5.85 | €5.60 | 3,905 | |
| €5.75 | -0.15 | -2.5% | €5.90 | €5.90 | €5.75 | 3,522 | |
| €5.90 | 0.00 | 0.0% | €5.90 | €6.00 | €5.90 | 288 | |
| €5.90 | 0.00 | 0.0% | €6.05 | €6.05 | €5.90 | 874 | |
| €5.90 | -0.20 | -3.3% | €6.10 | €6.10 | €5.90 | 3,368 | |
| €6.10 | 0.00 | 0.0% | €6.10 | €6.10 | €6.10 | 1,396 | |
| €6.10 | 0.00 | 0.0% | €6.10 | €6.15 | €6.10 | 358 | |
| €6.10 | +0.10 | +1.7% | €6.10 | €6.20 | €6.00 | 1,917 | |
| €6.00 | 0.00 | 0.0% | €6.10 | €6.10 | €6.00 | 1,581 | |
| €6.00 | 0.00 | 0.0% | €6.00 | €6.05 | €6.00 | 2,962 | |
| €6.00 | -0.30 | -4.8% | €6.10 | €6.10 | €6.00 | 2,437 | |
| €6.30 | +0.25 | +4.1% | €5.85 | €6.30 | €5.85 | 3,135 | |
| €6.05 | +0.05 | +0.8% | €6.10 | €6.10 | €5.85 | 8,287 | |
| €6.00 | -0.15 | -2.4% | €6.10 | €6.15 | €5.75 | 12,187 | |
| €6.15 | -0.05 | -0.8% | €6.15 | €6.20 | €6.15 | 1,770 | |
| €6.20 | 0.00 | 0.0% | €6.10 | €6.20 | €6.10 | 275 | |
| €6.20 | 0.00 | 0.0% | €6.30 | €6.30 | €6.20 | 1,004 | |
| €6.20 | -0.20 | -3.1% | €6.20 | €6.20 | €6.20 | 660 | |
| €6.40 | 0.00 | 0.0% | €6.30 | €6.40 | €6.30 | 294 | |
| €6.40 | +0.20 | +3.2% | €6.10 | €6.45 | €6.10 | 2,388 | |
| €6.20 | 0.00 | 0.0% | €6.20 | €6.20 | €6.20 | 3,990 | |
| €6.20 | 0.00 | 0.0% | €6.45 | €6.45 | €6.20 | 8 | |
| €6.20 | 0.00 | 0.0% | €6.20 | €6.20 | €6.20 | 1,730 | |
| €6.20 | 0.00 | 0.0% | €6.20 | €6.20 | €6.20 | 597 | |
| €6.20 | 0.00 | 0.0% | €6.20 | €6.20 | €6.20 | 74 | |
| €6.20 | 0.00 | 0.0% | €6.25 | €6.45 | €6.20 | 1,202 | |
| €6.20 | 0.00 | 0.0% | €6.20 | €6.20 | €6.20 | 2,293 | |
| €6.20 | -0.05 | -0.8% | €6.25 | €6.35 | €6.20 | 2,293 | |
| €6.25 | -0.05 | -0.8% | €6.30 | €6.30 | €6.25 | 3,849 | |
| €6.30 | -0.20 | -3.1% | €6.40 | €6.50 | €6.30 | 2,645 | |
| €6.50 | +0.15 | +2.4% | €6.50 | €6.50 | €6.50 | 2,000 | |
| €6.35 | +0.05 | +0.8% | €6.30 | €6.50 | €6.30 | 1,723 | |
| €6.30 | 0.00 | 0.0% | €6.30 | €6.30 | €6.30 | 493 | |
| €6.30 | 0.00 | 0.0% | €6.55 | €6.55 | €6.30 | 493 |
- Ticker
- BME:LAB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Madrid
- Currency
- EUR
What changed lately
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 66 slides
Labiana Health SA on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- Decks
- 3 decks · latest October 2026
Where Labiana Health SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:LAB · Home listing · This page | Madrid | Spain | EUR |
| Lang & Schwarz:A3DQE7 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3DQE7 | LS Exchange | Germany | EUR |
| Frankfurt:8RK | Frankfurt | Germany | EUR |
| Stuttgart:8RK | Stuttgart | Germany | EUR |
Valuation
P/E 15.7× against a median of 38.1×: the lowest of 2 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- €64.30M EUR
- P/E
- 15.7×
- EV/sales
- 0.9×
- EV/EBITDA
- 5.8×
- Price/book
- 8.0×
- Gross margin
- 61.2%
- Operating margin
- 9.7%
- Net margin
- 3.4%
- Debt to equity
- 5.9×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Labiana Health SA · BME:LAB | US$44.35M | US$70.57M | 15.7× | 0.9× | 5.8× | 8.0× | 3.4% | 5.9× | n/a |
| Celemics, Inc. · KRX:331920 | US$49.19M | US$32.45M | n/a | 8.4× | n/a | 2.2× | −260.9% | 0.5× | n/a |
| Lumos Diagnostics Holdings Ltd. · ASX:LDX | US$47.13M | US$37.64M | n/a | 2.8× | n/a | 2.1× | −37.5% | 0.3× | n/a |
| Renalytix PLC · LSE:RENX | US$45.66M | US$45.26M | n/a | 15.1× | n/a | n/a | −680.0% | n/a | n/a |
| Access Bio, Inc. · KRX:950130 | US$44.15M | −US$191.0M | n/a | −10.8× | n/a | 0.1× | −468.1% | 0.0× | n/a |
| EDX Medical Group plc · LSE:EDX | US$43.78M | US$39.96M | n/a | 92.3× | n/a | 15.4× | n/a | 0.0× | n/a |
| Osang Healthcare Co. Ltd. · KRX:036220 | US$42.35M | US$24.18M | n/a | 0.3× | n/a | 0.2× | −8.8% | 0.1× | n/a |
| ABL Diagnostics SA · EURONEXT:ABLD | US$41.27M | US$42.32M | 38.1× | 5.5× | 42.8× | 5.3× | 14.2% | 0.3× | n/a |
| hVIVO plc · LSE:HVO | US$41.02M | US$42.24M | n/a | 0.7× | 7.5× | 1.0× | −12.8% | 0.4× | n/a |
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| CytoGen, Inc. · KRX:217330 | US$38.58M | US$31.66M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| Median of the others | US$43.06M | US$38.80M | 38.1× | 2.2× | 28.4× | 2.1× | −37.5% | 0.3× | 1.34 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.50 EUR · Analysts' mean
- EPS, year to Dec 2026
- 0.78 · 1 analyst
- Revenue, year to Dec 2026
- 80.84M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Manuel Ramos | Presidente & CEO |
| Manuel Ramos Ortega | Chairman of the Board of Directors, CEO |
| Miquel Pujolriu | CFO |
| Miquel Pujolriu Giménez | Secretary not a member of the Board of Directors |
| Antonio Ortiz | Commercial Director of the Animal Division |
| Dragoljub Milinkovic | Managing Director of Zavod |
| Ivana Novoa | HR Director |
| Javier Sehabiaga | Operations Director, Human Division |
| José Manuel García | Commercial Director, Human Division |
| Mª Jesús Crespo | Director of R&D and Regulatory Affairs, Animal Division |
| Ramón Clavera | Operations Director, Animal Division |
| Sandra Villagrasa | General Director of Labiana Health |
| Sergio Jiménez | Director of Engineering, Maintenance, and EHS, Human Division |
| Suva Kaya | Managing Director of Zoleant |
| Tania Ubach | Commercial Director CMO, Animal Division |
| Xavier Pérez Ramos | Managing Director of the Animal Division |
Board
| Director | Role |
|---|---|
| Manuel Ramos Ortega | Chairman of the Board of Directors, CEO |
| Carmen Hortalà Vallvé | Vocal |
| John William Nellis | Member of the Appointments and Remuneration Committee |
| Juan Manuel Gil de Escobar Delgado | Member of the Appointments and Remuneration Committee |
| Juan Ortiz Hernández | Vocal |
| Sandra Villagrasa Clemente | Vocal |
| Wolfgang Johannes Storf | Chairman of the Appointments and Remuneration Committee |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 66 slides | October 2026 |
| Investor Presentation (October 2022) | Investor deck | 68 slides | Oct 25, 2022 |
| H1 2022 Earnings Presentation | Earnings | 27 slides | October 2022 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 75.2M | 66.3M | 58.5M | 57.8M | 57.0M | 57.8M |
| Cost of revenue | 29.2M | 25.3M | 24.1M | 25.4M | 21.6M | 23.8M |
| Gross profit | 46.0M | 40.9M | 34.3M | 32.5M | 35.4M | 34.1M |
| Selling, general and administrative | 22.7M | 18.2M | 17.9M | |||
| Operating income | 7.30M | 5.10M | -1.84M | -6.23M | 539.9K | 2.46M |
| Depreciation and amortization | 3.79M | 4.25M | 5.09M | 4.84M | 5.00M | |
| EBITDA | 11.1M | 9.35M | 3.24M | -1.39M | 5.54M | |
| Interest expense | 5.91M | 4.84M | 3.29M | 2.11M | 2.13M | |
| Income before tax | 1.20M | -30.0K | -5.27M | -7.84M | -2.12M | 541.2K |
| Net income | 2.57M | 253.4K | -4.42M | -8.94M | -1.78M | 1.07M |
| Earnings per share, basic | 0.36 | 0.04 | -0.61 | -1.25 | -0.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 5.91M | 6.74M | 2.96M | 2.52M | 3.28M |
| Short-term investments | 1.80K | 800 | 13.9K | 23.4K | 11.4K |
| Receivables | 10.4M | 9.42M | 11.8M | 8.78M | 7.93M |
| Inventory | 12.0M | 9.98M | 11.1M | 13.8M | 14.9M |
| Current assets | 31.5M | 28.7M | 29.0M | 28.8M | 29.4M |
| Property, plant and equipment | 20.6M | ||||
| Goodwill | -0 | -0 | -0 | 0 | 1.28M |
| Total assets | 57.5M | 52.0M | 59.1M | 60.8M | 68.4M |
| Accounts payable | 11.4M | 8.77M | 8.76M | 11.3M | 8.58M |
| Current liabilities | 22.7M | 22.2M | 24.7M | 35.1M | 30.5M |
| Long-term debt | 29.8M | 26.9M | 29.7M | 12.8M | 23.5M |
| Total liabilities | 52.8M | 49.4M | 55.7M | 53.0M | 56.8M |
| Shareholders' equity | 5.08M | 2.87M | 3.58M | 7.74M | 11.6M |
| Shares outstanding | 7.17M | 7.22M | 7.22M | 7.16M | 7.22M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | 1.70M | 7.19M | -1.83M | 4.68M | 3.91M |
| Capital spending | -4.44M | -3.05M | -2.85M | -5.45M | -4.77M |
| Free cash flow | -2.74M | 4.15M | -4.68M | -774.4K | -858.7K |
| Cash from investing | -2.95M | ||||
| Cash from financing | -2.50M | ||||
| Share buybacks | -158.9K | -158.6K | 4.17M | -1.13M | |
| Change in cash | -823.5K | 3.78M | 438.6K | -762.3K | 1.74M |
Cap table
Built by 6ix from Labiana Health SA’s releases
- Common shares
- 8,489,255
- Fully diluted
- 8,489,255
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,489,255 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,489,255 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Antonio Ortiz | Commercial Director of the Animal Division · Since at least Nov 5, 2026 |
| Dragoljub Milinkovic | Managing Director of Zavod · Since at least Nov 5, 2026 |
| Ivana Novoa | HR Director · Since at least Nov 5, 2026 |
| Javier Sehabiaga | Operations Director, Human Division · Since at least Nov 5, 2026 |
| José Manuel García | Commercial Director, Human Division · Since at least Nov 5, 2026 |
| Mª Jesús Crespo | Director of R&D and Regulatory Affairs, Animal Division · Since at least Nov 5, 2026 |
| Manuel Ramos | Presidente & CEO · Since at least Nov 5, 2026 |
| Miquel Pujolriu | CFO · Since at least Nov 5, 2026 |
| Ramón Clavera | Operations Director, Animal Division · Since at least Nov 5, 2026 |
| Sandra Villagrasa | General Director of Labiana Health · Since at least Nov 5, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Sergio Jiménez | Director of Engineering, Maintenance, and EHS, Human Division · Since at least Nov 5, 2026 |
| Suva Kaya | Managing Director of Zoleant · Since at least Nov 5, 2026 |
| Tania Ubach | Commercial Director CMO, Animal Division · Since at least Nov 5, 2026 |
| Xavier Pérez Ramos | Managing Director of the Animal Division · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Labiana Health SA.